GAIN THERAPEUTICS, INC Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
GAIN THERAPEUTICS, INC (GANX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $6.80 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-11
- GAIN THERAPEUTICS, INC other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was $6.80K, a 99.03% decline year-over-year.
- GAIN THERAPEUTICS, INC other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was $220.08K, a 72.37% increase year-over-year.
- GAIN THERAPEUTICS, INC other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $213.65K.
- GAIN THERAPEUTICS, INC other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$20.86K, a 109.06% decline year-over-year.
- GAIN THERAPEUTICS, INC other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $1.02M.
- GAIN THERAPEUTICS, INC other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$494.79K, a 333.82% decline from fiscal 2023.
- GAIN THERAPEUTICS, INC other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $211.61K, a 67.59% increase from fiscal 2022.
- GAIN THERAPEUTICS, INC other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was $126.27K, a 103.49% increase from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.80K 10-Q · filed 2026-08-11 | $226.88K 10-Q · filed 2026-08-11 | $440.53K derived: sum of 3 quarters · filed 2026-08-11 | $419.67K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $220.08K 10-Q · filed 2026-05-11 | $433.73K derived: sum of 2 quarters · filed 2026-05-11 | $412.87K derived: sum of 3 quarters · filed 2026-05-11 | $1.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $213.65K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $192.79K derived: sum of 2 quarters · filed 2026-03-26 | $896.73K derived: sum of 3 quarters · filed 2026-08-11 | $1.02M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$20.86K 10-Q · filed 2025-11-12 | $683.09K derived: sum of 2 quarters · filed 2026-08-11 | $810.77K 10-Q · filed 2025-11-12 | $320.41K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $703.95K 10-Q · filed 2026-08-11 | $831.63K 10-Q · filed 2026-08-11 | $341.27K derived: sum of 3 quarters · filed 2026-08-11 | $571.62K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $127.68K 10-Q · filed 2026-05-11 | -$362.68K derived: sum of 2 quarters · filed 2026-05-11 | -$132.33K derived: sum of 3 quarters · filed 2026-05-11 | -$141.73K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$490.36K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$260.01K derived: sum of 2 quarters · filed 2026-03-26 | -$269.41K derived: sum of 3 quarters · filed 2026-03-26 | -$494.79K 10-K · filed 2026-03-26 |
| 2024-09-30 | $230.35K 10-Q · filed 2025-11-12 | $220.95K derived: sum of 2 quarters · filed 2025-11-12 | -$4.43K 10-Q · filed 2025-11-12 | $152.15K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$9.40K 10-Q · filed 2025-08-12 | -$234.78K 10-Q · filed 2025-08-12 | -$78.20K derived: sum of 3 quarters · filed 2025-08-12 | -$121.86K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$225.38K 10-Q · filed 2025-05-14 | -$68.80K derived: sum of 2 quarters · filed 2025-05-14 | -$112.46K derived: sum of 3 quarters · filed 2025-05-14 | -$74.45K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $156.58K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $112.92K derived: sum of 2 quarters · filed 2025-03-27 | $150.93K derived: sum of 3 quarters · filed 2025-03-27 | $211.61K 10-K · filed 2025-03-27 |
| 2023-09-30 | -$43.66K 10-Q · filed 2024-11-14 | -$5.65K derived: sum of 2 quarters · filed 2024-11-14 | $55.03K 10-Q · filed 2024-11-14 | $387.56K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $38.01K 10-Q · filed 2024-08-08 | $98.70K 10-Q · filed 2024-08-08 | $431.22K derived: sum of 3 quarters · filed 2024-08-08 | $279.89K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $60.68K 10-Q · filed 2024-05-14 | $393.21K derived: sum of 2 quarters · filed 2024-05-14 | $241.88K derived: sum of 3 quarters · filed 2024-05-14 | $210.61K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $332.53K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $181.19K derived: sum of 2 quarters · filed 2024-03-26 | $149.93K derived: sum of 3 quarters · filed 2024-03-26 | $126.27K 10-K · filed 2024-03-26 |
| 2022-09-30 | -$151.33K 10-Q · filed 2023-11-14 | -$182.60K derived: sum of 2 quarters · filed 2023-11-14 | -$206.25K 10-Q · filed 2023-11-14 | -$184.82K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$31.27K 10-Q · filed 2023-08-10 | -$54.92K 10-Q · filed 2023-08-10 | -$33.49K derived: sum of 3 quarters · filed 2023-08-10 | $18.55K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$23.66K 10-Q · filed 2023-05-12 | -$2.22K derived: sum of 2 quarters · filed 2023-05-12 | $49.82K derived: sum of 3 quarters · filed 2023-05-12 | $42.56K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $21.43K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $73.47K derived: sum of 2 quarters · filed 2023-03-23 | $66.22K derived: sum of 3 quarters · filed 2023-03-23 | $62.05K 10-K · filed 2023-03-23 |
| 2021-09-30 | $52.04K 10-Q · filed 2022-11-10 | $44.78K derived: sum of 2 quarters · filed 2022-11-10 | $40.62K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$7.26K 10-Q · filed 2022-08-08 | -$11.42K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | -$4.16K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | -$71.53K 10-K · filed 2022-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |